Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
33,560
archived clinical trials in
Neurology

Glyburide Advantage in Malignant Edema and Stroke - Remedy Pharmaceuticals
A Randomized, Multi-center, Prospective, Double Blind, Two-stage, Adaptive Phase II Trial of RP- 1127 (Glyburide for Injection) in Patients With a Severe Anterior Circulation Ischemic Stroke Who Are Likely to Develop Malignant Edema
Status: Enrolling
Updated:  6/3/2014
Maine Medical Center
mi
from
Scarborough, ME
Glyburide Advantage in Malignant Edema and Stroke - Remedy Pharmaceuticals
A Randomized, Multi-center, Prospective, Double Blind, Two-stage, Adaptive Phase II Trial of RP- 1127 (Glyburide for Injection) in Patients With a Severe Anterior Circulation Ischemic Stroke Who Are Likely to Develop Malignant Edema
Status: Enrolling
Updated: 6/3/2014
Maine Medical Center
mi
from
Scarborough, ME
Click here to add this to my saved trials
Glyburide Advantage in Malignant Edema and Stroke - Remedy Pharmaceuticals
A Randomized, Multi-center, Prospective, Double Blind, Two-stage, Adaptive Phase II Trial of RP- 1127 (Glyburide for Injection) in Patients With a Severe Anterior Circulation Ischemic Stroke Who Are Likely to Develop Malignant Edema
Status: Enrolling
Updated:  6/3/2014
University of Maryland School of Medicine
mi
from
Baltimore, MD
Glyburide Advantage in Malignant Edema and Stroke - Remedy Pharmaceuticals
A Randomized, Multi-center, Prospective, Double Blind, Two-stage, Adaptive Phase II Trial of RP- 1127 (Glyburide for Injection) in Patients With a Severe Anterior Circulation Ischemic Stroke Who Are Likely to Develop Malignant Edema
Status: Enrolling
Updated: 6/3/2014
University of Maryland School of Medicine
mi
from
Baltimore, MD
Click here to add this to my saved trials
Glyburide Advantage in Malignant Edema and Stroke - Remedy Pharmaceuticals
A Randomized, Multi-center, Prospective, Double Blind, Two-stage, Adaptive Phase II Trial of RP- 1127 (Glyburide for Injection) in Patients With a Severe Anterior Circulation Ischemic Stroke Who Are Likely to Develop Malignant Edema
Status: Enrolling
Updated:  6/3/2014
Massachusetts General Hospital
mi
from
Boston, MA
Glyburide Advantage in Malignant Edema and Stroke - Remedy Pharmaceuticals
A Randomized, Multi-center, Prospective, Double Blind, Two-stage, Adaptive Phase II Trial of RP- 1127 (Glyburide for Injection) in Patients With a Severe Anterior Circulation Ischemic Stroke Who Are Likely to Develop Malignant Edema
Status: Enrolling
Updated: 6/3/2014
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Glyburide Advantage in Malignant Edema and Stroke - Remedy Pharmaceuticals
A Randomized, Multi-center, Prospective, Double Blind, Two-stage, Adaptive Phase II Trial of RP- 1127 (Glyburide for Injection) in Patients With a Severe Anterior Circulation Ischemic Stroke Who Are Likely to Develop Malignant Edema
Status: Enrolling
Updated:  6/3/2014
Umass Memorial Medical Center
mi
from
Worcester, MA
Glyburide Advantage in Malignant Edema and Stroke - Remedy Pharmaceuticals
A Randomized, Multi-center, Prospective, Double Blind, Two-stage, Adaptive Phase II Trial of RP- 1127 (Glyburide for Injection) in Patients With a Severe Anterior Circulation Ischemic Stroke Who Are Likely to Develop Malignant Edema
Status: Enrolling
Updated: 6/3/2014
Umass Memorial Medical Center
mi
from
Worcester, MA
Click here to add this to my saved trials
Glyburide Advantage in Malignant Edema and Stroke - Remedy Pharmaceuticals
A Randomized, Multi-center, Prospective, Double Blind, Two-stage, Adaptive Phase II Trial of RP- 1127 (Glyburide for Injection) in Patients With a Severe Anterior Circulation Ischemic Stroke Who Are Likely to Develop Malignant Edema
Status: Enrolling
Updated:  6/3/2014
Cleveland Clinic
mi
from
Cleveland, OH
Glyburide Advantage in Malignant Edema and Stroke - Remedy Pharmaceuticals
A Randomized, Multi-center, Prospective, Double Blind, Two-stage, Adaptive Phase II Trial of RP- 1127 (Glyburide for Injection) in Patients With a Severe Anterior Circulation Ischemic Stroke Who Are Likely to Develop Malignant Edema
Status: Enrolling
Updated: 6/3/2014
Cleveland Clinic
mi
from
Cleveland, OH
Click here to add this to my saved trials
Glyburide Advantage in Malignant Edema and Stroke - Remedy Pharmaceuticals
A Randomized, Multi-center, Prospective, Double Blind, Two-stage, Adaptive Phase II Trial of RP- 1127 (Glyburide for Injection) in Patients With a Severe Anterior Circulation Ischemic Stroke Who Are Likely to Develop Malignant Edema
Status: Enrolling
Updated:  6/3/2014
The Ohio State University, Wexner Medical Center
mi
from
Columbus, OH
Glyburide Advantage in Malignant Edema and Stroke - Remedy Pharmaceuticals
A Randomized, Multi-center, Prospective, Double Blind, Two-stage, Adaptive Phase II Trial of RP- 1127 (Glyburide for Injection) in Patients With a Severe Anterior Circulation Ischemic Stroke Who Are Likely to Develop Malignant Edema
Status: Enrolling
Updated: 6/3/2014
The Ohio State University, Wexner Medical Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Glyburide Advantage in Malignant Edema and Stroke - Remedy Pharmaceuticals
A Randomized, Multi-center, Prospective, Double Blind, Two-stage, Adaptive Phase II Trial of RP- 1127 (Glyburide for Injection) in Patients With a Severe Anterior Circulation Ischemic Stroke Who Are Likely to Develop Malignant Edema
Status: Enrolling
Updated:  6/3/2014
Oregon Health & Science University Hospital
mi
from
Portland, OR
Glyburide Advantage in Malignant Edema and Stroke - Remedy Pharmaceuticals
A Randomized, Multi-center, Prospective, Double Blind, Two-stage, Adaptive Phase II Trial of RP- 1127 (Glyburide for Injection) in Patients With a Severe Anterior Circulation Ischemic Stroke Who Are Likely to Develop Malignant Edema
Status: Enrolling
Updated: 6/3/2014
Oregon Health & Science University Hospital
mi
from
Portland, OR
Click here to add this to my saved trials
Glyburide Advantage in Malignant Edema and Stroke - Remedy Pharmaceuticals
A Randomized, Multi-center, Prospective, Double Blind, Two-stage, Adaptive Phase II Trial of RP- 1127 (Glyburide for Injection) in Patients With a Severe Anterior Circulation Ischemic Stroke Who Are Likely to Develop Malignant Edema
Status: Enrolling
Updated:  6/3/2014
Abington Memorial Hospital
mi
from
Abington, PA
Glyburide Advantage in Malignant Edema and Stroke - Remedy Pharmaceuticals
A Randomized, Multi-center, Prospective, Double Blind, Two-stage, Adaptive Phase II Trial of RP- 1127 (Glyburide for Injection) in Patients With a Severe Anterior Circulation Ischemic Stroke Who Are Likely to Develop Malignant Edema
Status: Enrolling
Updated: 6/3/2014
Abington Memorial Hospital
mi
from
Abington, PA
Click here to add this to my saved trials
Glyburide Advantage in Malignant Edema and Stroke - Remedy Pharmaceuticals
A Randomized, Multi-center, Prospective, Double Blind, Two-stage, Adaptive Phase II Trial of RP- 1127 (Glyburide for Injection) in Patients With a Severe Anterior Circulation Ischemic Stroke Who Are Likely to Develop Malignant Edema
Status: Enrolling
Updated:  6/3/2014
UPMC Presbyterian Hospital
mi
from
Pittsburgh, PA
Glyburide Advantage in Malignant Edema and Stroke - Remedy Pharmaceuticals
A Randomized, Multi-center, Prospective, Double Blind, Two-stage, Adaptive Phase II Trial of RP- 1127 (Glyburide for Injection) in Patients With a Severe Anterior Circulation Ischemic Stroke Who Are Likely to Develop Malignant Edema
Status: Enrolling
Updated: 6/3/2014
UPMC Presbyterian Hospital
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Glyburide Advantage in Malignant Edema and Stroke - Remedy Pharmaceuticals
A Randomized, Multi-center, Prospective, Double Blind, Two-stage, Adaptive Phase II Trial of RP- 1127 (Glyburide for Injection) in Patients With a Severe Anterior Circulation Ischemic Stroke Who Are Likely to Develop Malignant Edema
Status: Enrolling
Updated:  6/3/2014
Medical University of South Carolina
mi
from
Charleston, SC
Glyburide Advantage in Malignant Edema and Stroke - Remedy Pharmaceuticals
A Randomized, Multi-center, Prospective, Double Blind, Two-stage, Adaptive Phase II Trial of RP- 1127 (Glyburide for Injection) in Patients With a Severe Anterior Circulation Ischemic Stroke Who Are Likely to Develop Malignant Edema
Status: Enrolling
Updated: 6/3/2014
Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
Glyburide Advantage in Malignant Edema and Stroke - Remedy Pharmaceuticals
A Randomized, Multi-center, Prospective, Double Blind, Two-stage, Adaptive Phase II Trial of RP- 1127 (Glyburide for Injection) in Patients With a Severe Anterior Circulation Ischemic Stroke Who Are Likely to Develop Malignant Edema
Status: Enrolling
Updated:  6/3/2014
University of Utah Healthcare
mi
from
Salt Lake City, UT
Glyburide Advantage in Malignant Edema and Stroke - Remedy Pharmaceuticals
A Randomized, Multi-center, Prospective, Double Blind, Two-stage, Adaptive Phase II Trial of RP- 1127 (Glyburide for Injection) in Patients With a Severe Anterior Circulation Ischemic Stroke Who Are Likely to Develop Malignant Edema
Status: Enrolling
Updated: 6/3/2014
University of Utah Healthcare
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Hypothalamic Injury
Randomized, Double-Blind, Placebo Controlled, Phase 2a Trial of ZGN-440 (Subcutaneous Beloranib in Suspension), A Novel Methionine Aminopeptidase 2 Inhibitor, in Obese Subjects With Hypothalamic Injury to Evaluate Weight Reduction and Safety Over 4 Weeks Followed by an Optional 4-Week Open-Label Extension
Status: Enrolling
Updated:  6/3/2014
Childrens Hospitals And Clinics Of Minnesota
mi
from
St. Paul, MN
An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Hypothalamic Injury
Randomized, Double-Blind, Placebo Controlled, Phase 2a Trial of ZGN-440 (Subcutaneous Beloranib in Suspension), A Novel Methionine Aminopeptidase 2 Inhibitor, in Obese Subjects With Hypothalamic Injury to Evaluate Weight Reduction and Safety Over 4 Weeks Followed by an Optional 4-Week Open-Label Extension
Status: Enrolling
Updated: 6/3/2014
Childrens Hospitals And Clinics Of Minnesota
mi
from
St. Paul, MN
Click here to add this to my saved trials
An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Hypothalamic Injury
Randomized, Double-Blind, Placebo Controlled, Phase 2a Trial of ZGN-440 (Subcutaneous Beloranib in Suspension), A Novel Methionine Aminopeptidase 2 Inhibitor, in Obese Subjects With Hypothalamic Injury to Evaluate Weight Reduction and Safety Over 4 Weeks Followed by an Optional 4-Week Open-Label Extension
Status: Enrolling
Updated:  6/3/2014
Vanderbilt University Medical Center
mi
from
Nashville, TN
An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Hypothalamic Injury
Randomized, Double-Blind, Placebo Controlled, Phase 2a Trial of ZGN-440 (Subcutaneous Beloranib in Suspension), A Novel Methionine Aminopeptidase 2 Inhibitor, in Obese Subjects With Hypothalamic Injury to Evaluate Weight Reduction and Safety Over 4 Weeks Followed by an Optional 4-Week Open-Label Extension
Status: Enrolling
Updated: 6/3/2014
Vanderbilt University Medical Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Constraint Induced Movement Therapy Summer Camp
Constraint Induced Movement Therapy Summer Camp for Children With Unilateral Cerebral Palsy Ages 3-7
Status: Enrolling
Updated:  6/3/2014
Nationwide Children's Hospital
mi
from
Columbus, OH
Constraint Induced Movement Therapy Summer Camp
Constraint Induced Movement Therapy Summer Camp for Children With Unilateral Cerebral Palsy Ages 3-7
Status: Enrolling
Updated: 6/3/2014
Nationwide Children's Hospital
mi
from
Columbus, OH
Click here to add this to my saved trials
Lipoic Acid and Omega-3 Fatty Acids for Cognitive Impairment in Multiple Sclerosis
Lipoic Acid and Omega-3 Fatty Acids for Cognitive Impairment in Multiple Sclerosis
Status: Enrolling
Updated:  6/5/2014
Oregon Health and Science University
mi
from
Portland, OR
Lipoic Acid and Omega-3 Fatty Acids for Cognitive Impairment in Multiple Sclerosis
Lipoic Acid and Omega-3 Fatty Acids for Cognitive Impairment in Multiple Sclerosis
Status: Enrolling
Updated: 6/5/2014
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
Hyperbaric Oxygen Treatment to Treat Mild Traumatic Brain Injury (mTBI)/Persistent Post-Concussion Syndrome (PPCS)
Hyperbaric Oxygen Therapy Treatment of Chronic Mild Traumatic Brain Injury (mTBI)/Persistent Post-Concussion Syndrome (PPCS)
Status: Enrolling
Updated:  6/9/2014
Louisiana State University Health Sciences Center- New Orleans
mi
from
New Orleans, LA
Hyperbaric Oxygen Treatment to Treat Mild Traumatic Brain Injury (mTBI)/Persistent Post-Concussion Syndrome (PPCS)
Hyperbaric Oxygen Therapy Treatment of Chronic Mild Traumatic Brain Injury (mTBI)/Persistent Post-Concussion Syndrome (PPCS)
Status: Enrolling
Updated: 6/9/2014
Louisiana State University Health Sciences Center- New Orleans
mi
from
New Orleans, LA
Click here to add this to my saved trials
Virtual Reality-Based Exercise in Cancer Patients
Virtual Reality-Based Exercise in Cancer Patients With Chemotherapy Induced Peripheral Neuropathy
Status: Enrolling
Updated:  6/16/2014
University of Arizona Cancer Center
mi
from
Tucson, AZ
Virtual Reality-Based Exercise in Cancer Patients
Virtual Reality-Based Exercise in Cancer Patients With Chemotherapy Induced Peripheral Neuropathy
Status: Enrolling
Updated: 6/16/2014
University of Arizona Cancer Center
mi
from
Tucson, AZ
Click here to add this to my saved trials
Pilot Study of Melatonin and Epilepsy
Melatonin and Sleep in Patients With Epilepsy
Status: Enrolling
Updated:  6/17/2014
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Pilot Study of Melatonin and Epilepsy
Melatonin and Sleep in Patients With Epilepsy
Status: Enrolling
Updated: 6/17/2014
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Simvastatin in Aneurysmal Subarachnoid Haemorrhage (STASH) a Multicentre Randomised Controlled Clinical Trial
Simvastatin in Aneurysmal Subarachnoid Haemorrhage (STASH) a Multicentre Randomised Controlled Clinical Trial
Status: Enrolling
Updated:  6/24/2014
Dept of Neurological Surgery, University of Florida
mi
from
Gainesville, FL
Simvastatin in Aneurysmal Subarachnoid Haemorrhage (STASH) a Multicentre Randomised Controlled Clinical Trial
Simvastatin in Aneurysmal Subarachnoid Haemorrhage (STASH) a Multicentre Randomised Controlled Clinical Trial
Status: Enrolling
Updated: 6/24/2014
Dept of Neurological Surgery, University of Florida
mi
from
Gainesville, FL
Click here to add this to my saved trials
Simvastatin in Aneurysmal Subarachnoid Haemorrhage (STASH) a Multicentre Randomised Controlled Clinical Trial
Simvastatin in Aneurysmal Subarachnoid Haemorrhage (STASH) a Multicentre Randomised Controlled Clinical Trial
Status: Enrolling
Updated:  6/24/2014
Mayo Clinic
mi
from
Jacksonville, FL
Simvastatin in Aneurysmal Subarachnoid Haemorrhage (STASH) a Multicentre Randomised Controlled Clinical Trial
Simvastatin in Aneurysmal Subarachnoid Haemorrhage (STASH) a Multicentre Randomised Controlled Clinical Trial
Status: Enrolling
Updated: 6/24/2014
Mayo Clinic
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Variability of Molecular Biomarkers and Clinical Measures in People With Myotonic Dystrophy Type 1
A Multicenter Observational Study to Assess the Variability of Molecular Biomarkers and Clinical Measures in Patients With Myotonic Dystrophy Type 1
Status: Enrolling
Updated:  6/24/2014
National Institutes of Health Clinical Center
mi
from
Bethesda, MD
Variability of Molecular Biomarkers and Clinical Measures in People With Myotonic Dystrophy Type 1
A Multicenter Observational Study to Assess the Variability of Molecular Biomarkers and Clinical Measures in Patients With Myotonic Dystrophy Type 1
Status: Enrolling
Updated: 6/24/2014
National Institutes of Health Clinical Center
mi
from
Bethesda, MD
Click here to add this to my saved trials
Pilot Study to Evaluate MR-guided Laser Ablation of Focal Lesions in Patients With Medically Refractory Partial Epilepsy
A Pilot Study to Evaluate MR-guided Laser Ablation of Focal Lesions in Patients With Medically Refractory Partial Epilepsy
Status: Enrolling
Updated:  6/30/2014
Mayo Clinic Florida
mi
from
Jacksonville, FL
Pilot Study to Evaluate MR-guided Laser Ablation of Focal Lesions in Patients With Medically Refractory Partial Epilepsy
A Pilot Study to Evaluate MR-guided Laser Ablation of Focal Lesions in Patients With Medically Refractory Partial Epilepsy
Status: Enrolling
Updated: 6/30/2014
Mayo Clinic Florida
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Pilot Study to Evaluate MR-guided Laser Ablation of Focal Lesions in Patients With Medically Refractory Partial Epilepsy
A Pilot Study to Evaluate MR-guided Laser Ablation of Focal Lesions in Patients With Medically Refractory Partial Epilepsy
Status: Enrolling
Updated:  6/30/2014
Mayo Clinic Rochester
mi
from
Rochester, MN
Pilot Study to Evaluate MR-guided Laser Ablation of Focal Lesions in Patients With Medically Refractory Partial Epilepsy
A Pilot Study to Evaluate MR-guided Laser Ablation of Focal Lesions in Patients With Medically Refractory Partial Epilepsy
Status: Enrolling
Updated: 6/30/2014
Mayo Clinic Rochester
mi
from
Rochester, MN
Click here to add this to my saved trials
Improving Outcomes After Traumatic Injury: A Goal Management Approach
Status: Enrolling
Updated:  7/2/2014
Vanderbilt University Medical Center
mi
from
Nashville, TN
Improving Outcomes After Traumatic Injury: A Goal Management Approach
Status: Enrolling
Updated: 7/2/2014
Vanderbilt University Medical Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Identification of Diagnostic And Prognostic Biomarkers From Amyotrophic Lateral Sclerosis (ALS) Skin and Adipose Samples
Identification of Diagnostic and Prognostic Biomarkers From Amyotrophic Lateral Sclerosis (ALS) Skin and Adipose Samples
Status: Enrolling
Updated:  7/2/2014
Carolinas Medical Center - Dept of Neurology
mi
from
Charlotte, NC
Identification of Diagnostic And Prognostic Biomarkers From Amyotrophic Lateral Sclerosis (ALS) Skin and Adipose Samples
Identification of Diagnostic and Prognostic Biomarkers From Amyotrophic Lateral Sclerosis (ALS) Skin and Adipose Samples
Status: Enrolling
Updated: 7/2/2014
Carolinas Medical Center - Dept of Neurology
mi
from
Charlotte, NC
Click here to add this to my saved trials
Establishment of Phenotypic Profiles of Muscular Dystrophies for Understanding Disease Progression, Diagnosis and Development of New Therapies
Status: Enrolling
Updated:  7/2/2014
Carolinas Medical Center - Dept of Neurology
mi
from
Charlotte, NC
Establishment of Phenotypic Profiles of Muscular Dystrophies for Understanding Disease Progression, Diagnosis and Development of New Therapies
Status: Enrolling
Updated: 7/2/2014
Carolinas Medical Center - Dept of Neurology
mi
from
Charlotte, NC
Click here to add this to my saved trials
Establishment of a Tissue Bank (Blood, CSF) for the Understanding of the Disease Progression and Early Diagnosis of Motor Neuron Disease (MND)
Establishment of a Tissue Bank (Blood, CSF) for the Understanding of the Disease Progression and Early Diagnosis of Motor Neuron Disease (MND).
Status: Enrolling
Updated:  7/2/2014
Carolinas Medical Center - Dept of Neurology
mi
from
Charlotte, NC
Establishment of a Tissue Bank (Blood, CSF) for the Understanding of the Disease Progression and Early Diagnosis of Motor Neuron Disease (MND)
Establishment of a Tissue Bank (Blood, CSF) for the Understanding of the Disease Progression and Early Diagnosis of Motor Neuron Disease (MND).
Status: Enrolling
Updated: 7/2/2014
Carolinas Medical Center - Dept of Neurology
mi
from
Charlotte, NC
Click here to add this to my saved trials
Association of Endothelial Function and Clinical Outcomes in Subjects Admitted to Chest Pain Unit
The Impact of Short- and Long-term Endothelial Function Assessment by Peripheral Arterial Tonometry (PAT) on Clinical Outcome in Subjects Admitted to Chest Pain Unit (CPU)
Status: Enrolling
Updated:  7/6/2014
Mayo Clinic Chest Pain Unit, Emergency Department
mi
from
Rochester, MN
Association of Endothelial Function and Clinical Outcomes in Subjects Admitted to Chest Pain Unit
The Impact of Short- and Long-term Endothelial Function Assessment by Peripheral Arterial Tonometry (PAT) on Clinical Outcome in Subjects Admitted to Chest Pain Unit (CPU)
Status: Enrolling
Updated: 7/6/2014
Mayo Clinic Chest Pain Unit, Emergency Department
mi
from
Rochester, MN
Click here to add this to my saved trials
Methylphenidate Treatment of Attention Deficits in Epilepsy
Methylphenidate Treatment of Attentional and Cognitive Deficits in Epilepsy
Status: Enrolling
Updated:  7/9/2014
Stanford University
mi
from
Palo Alto, CA
Methylphenidate Treatment of Attention Deficits in Epilepsy
Methylphenidate Treatment of Attentional and Cognitive Deficits in Epilepsy
Status: Enrolling
Updated: 7/9/2014
Stanford University
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Safety, Tolerability, and Pharmacokinetics of Multiple Rising Doses of TAK-137 in Adults With Attention-Deficit/Hyperactivity Disorder
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability, and Pharmacokinetic Study of Multiple Rising Doses of TAK-137 in Adult Subjects With Attention-Deficit/Hyperactivity Disorder
Status: Enrolling
Updated:  7/15/2014
Clinical Research Facility
mi
from
Marlton, NY
Safety, Tolerability, and Pharmacokinetics of Multiple Rising Doses of TAK-137 in Adults With Attention-Deficit/Hyperactivity Disorder
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability, and Pharmacokinetic Study of Multiple Rising Doses of TAK-137 in Adult Subjects With Attention-Deficit/Hyperactivity Disorder
Status: Enrolling
Updated: 7/15/2014
Clinical Research Facility
mi
from
Marlton, NY
Click here to add this to my saved trials
Incobotulinum Toxin A (Xeomin®) for Troublesome Sialorrhea in Parkinson's Disease (PD)/Parkinsonism
Randomized Double Blind Placebo Controlled Cross-Over Study of Incobotulinum Toxin A (Xeomin®) for Troublesome Sialorrhea in Parkinson's Disease (PD)/Parkinsonism
Status: Enrolling
Updated:  7/17/2014
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Incobotulinum Toxin A (Xeomin®) for Troublesome Sialorrhea in Parkinson's Disease (PD)/Parkinsonism
Randomized Double Blind Placebo Controlled Cross-Over Study of Incobotulinum Toxin A (Xeomin®) for Troublesome Sialorrhea in Parkinson's Disease (PD)/Parkinsonism
Status: Enrolling
Updated: 7/17/2014
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Fluoxetine for Motor, Aphasia, and Neglect Recovery After Ischemic Stroke
Pilot RCT of Fluoxetine vs Placebo to Treat Motor, Language and Unilateral Neglect After Ischemic Stroke
Status: Enrolling
Updated:  7/17/2014
Spaulding Rehabilitation Hospital
mi
from
Boston, MA
Fluoxetine for Motor, Aphasia, and Neglect Recovery After Ischemic Stroke
Pilot RCT of Fluoxetine vs Placebo to Treat Motor, Language and Unilateral Neglect After Ischemic Stroke
Status: Enrolling
Updated: 7/17/2014
Spaulding Rehabilitation Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Using Video Modeled Social Stories to Improve Oral Hygiene in Children With Autism Spectrum Disorder
Using Video Modeled Social Stories to Improve Oral Hygiene in Children With Autism
Status: Enrolling
Updated:  7/21/2014
Yale New Haven Hospital Pediatric Dental Center
mi
from
New Haven, CT
Using Video Modeled Social Stories to Improve Oral Hygiene in Children With Autism Spectrum Disorder
Using Video Modeled Social Stories to Improve Oral Hygiene in Children With Autism
Status: Enrolling
Updated: 7/21/2014
Yale New Haven Hospital Pediatric Dental Center
mi
from
New Haven, CT
Click here to add this to my saved trials
Using Video Modeled Social Stories to Improve Oral Hygiene in Children With Autism Spectrum Disorder
Using Video Modeled Social Stories to Improve Oral Hygiene in Children With Autism
Status: Enrolling
Updated:  7/21/2014
Yale Pediatric Dental Center Suite 403
mi
from
New Haven, CT
Using Video Modeled Social Stories to Improve Oral Hygiene in Children With Autism Spectrum Disorder
Using Video Modeled Social Stories to Improve Oral Hygiene in Children With Autism
Status: Enrolling
Updated: 7/21/2014
Yale Pediatric Dental Center Suite 403
mi
from
New Haven, CT
Click here to add this to my saved trials
Effects of a Homeopathic Anti-inflammatory Topical Cream on Ulcers and Neuropathy in the Diabetic Foot
A Double Blind Placebo Controlled Pilot Study to Evaluate the Effects of a Homeopathic Anti-inflammatory Topical Cream on the Healing of Wounds That Develop Into Ulcers and Neuropathy in the Diabetic Foot.
Status: Enrolling
Updated:  7/22/2014
Calvary Hospital Wound Care Clinic
mi
from
Bronx, NY
Effects of a Homeopathic Anti-inflammatory Topical Cream on Ulcers and Neuropathy in the Diabetic Foot
A Double Blind Placebo Controlled Pilot Study to Evaluate the Effects of a Homeopathic Anti-inflammatory Topical Cream on the Healing of Wounds That Develop Into Ulcers and Neuropathy in the Diabetic Foot.
Status: Enrolling
Updated: 7/22/2014
Calvary Hospital Wound Care Clinic
mi
from
Bronx, NY
Click here to add this to my saved trials
A Study of ALKS 8700, a Monomethyl Fumarate (MMF) Molecule, in Healthy Adults
A Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Oral ALKS 8700 in Healthy Adults
Status: Enrolling
Updated:  7/24/2014
Alkermes Study Site
mi
from
Austin, TX
A Study of ALKS 8700, a Monomethyl Fumarate (MMF) Molecule, in Healthy Adults
A Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Oral ALKS 8700 in Healthy Adults
Status: Enrolling
Updated: 7/24/2014
Alkermes Study Site
mi
from
Austin, TX
Click here to add this to my saved trials
First Time Use of SD-809 in Huntington Disease
A Randomized Double Blind, Placebo Controlled Study of SD-809 Extended Release for the Treatment of Chorea Associated With Huntington Disease
Status: Enrolling
Updated:  7/31/2014
Clinical Research Facility
mi
from
Albany, NY
First Time Use of SD-809 in Huntington Disease
A Randomized Double Blind, Placebo Controlled Study of SD-809 Extended Release for the Treatment of Chorea Associated With Huntington Disease
Status: Enrolling
Updated: 7/31/2014
Clinical Research Facility
mi
from
Albany, NY
Click here to add this to my saved trials
First Time Use of SD-809 in Huntington Disease
A Randomized Double Blind, Placebo Controlled Study of SD-809 Extended Release for the Treatment of Chorea Associated With Huntington Disease
Status: Enrolling
Updated:  7/31/2014
Clinical Research Facility
mi
from
Fayetteville, AR
First Time Use of SD-809 in Huntington Disease
A Randomized Double Blind, Placebo Controlled Study of SD-809 Extended Release for the Treatment of Chorea Associated With Huntington Disease
Status: Enrolling
Updated: 7/31/2014
Clinical Research Facility
mi
from
Fayetteville, AR
Click here to add this to my saved trials
First Time Use of SD-809 in Huntington Disease
A Randomized Double Blind, Placebo Controlled Study of SD-809 Extended Release for the Treatment of Chorea Associated With Huntington Disease
Status: Enrolling
Updated:  7/31/2014
Clinical Research Facility
mi
from
Los Angeles, CA
First Time Use of SD-809 in Huntington Disease
A Randomized Double Blind, Placebo Controlled Study of SD-809 Extended Release for the Treatment of Chorea Associated With Huntington Disease
Status: Enrolling
Updated: 7/31/2014
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
First Time Use of SD-809 in Huntington Disease
A Randomized Double Blind, Placebo Controlled Study of SD-809 Extended Release for the Treatment of Chorea Associated With Huntington Disease
Status: Enrolling
Updated:  7/31/2014
Clinical Research Facility
mi
from
Englewood, CO
First Time Use of SD-809 in Huntington Disease
A Randomized Double Blind, Placebo Controlled Study of SD-809 Extended Release for the Treatment of Chorea Associated With Huntington Disease
Status: Enrolling
Updated: 7/31/2014
Clinical Research Facility
mi
from
Englewood, CO
Click here to add this to my saved trials
First Time Use of SD-809 in Huntington Disease
A Randomized Double Blind, Placebo Controlled Study of SD-809 Extended Release for the Treatment of Chorea Associated With Huntington Disease
Status: Enrolling
Updated:  7/31/2014
Clinical Research Facility
mi
from
Washington,
First Time Use of SD-809 in Huntington Disease
A Randomized Double Blind, Placebo Controlled Study of SD-809 Extended Release for the Treatment of Chorea Associated With Huntington Disease
Status: Enrolling
Updated: 7/31/2014
Clinical Research Facility
mi
from
Washington,
Click here to add this to my saved trials
First Time Use of SD-809 in Huntington Disease
A Randomized Double Blind, Placebo Controlled Study of SD-809 Extended Release for the Treatment of Chorea Associated With Huntington Disease
Status: Enrolling
Updated:  7/31/2014
Clinical Research Facility
mi
from
Boca Raton, FL
First Time Use of SD-809 in Huntington Disease
A Randomized Double Blind, Placebo Controlled Study of SD-809 Extended Release for the Treatment of Chorea Associated With Huntington Disease
Status: Enrolling
Updated: 7/31/2014
Clinical Research Facility
mi
from
Boca Raton, FL
Click here to add this to my saved trials
First Time Use of SD-809 in Huntington Disease
A Randomized Double Blind, Placebo Controlled Study of SD-809 Extended Release for the Treatment of Chorea Associated With Huntington Disease
Status: Enrolling
Updated:  7/31/2014
Clinical Research Facility
mi
from
Gainesville, FL
First Time Use of SD-809 in Huntington Disease
A Randomized Double Blind, Placebo Controlled Study of SD-809 Extended Release for the Treatment of Chorea Associated With Huntington Disease
Status: Enrolling
Updated: 7/31/2014
Clinical Research Facility
mi
from
Gainesville, FL
Click here to add this to my saved trials
First Time Use of SD-809 in Huntington Disease
A Randomized Double Blind, Placebo Controlled Study of SD-809 Extended Release for the Treatment of Chorea Associated With Huntington Disease
Status: Enrolling
Updated:  7/31/2014
Clinical Research Facility
mi
from
Miami, FL
First Time Use of SD-809 in Huntington Disease
A Randomized Double Blind, Placebo Controlled Study of SD-809 Extended Release for the Treatment of Chorea Associated With Huntington Disease
Status: Enrolling
Updated: 7/31/2014
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials
First Time Use of SD-809 in Huntington Disease
A Randomized Double Blind, Placebo Controlled Study of SD-809 Extended Release for the Treatment of Chorea Associated With Huntington Disease
Status: Enrolling
Updated:  7/31/2014
Clinical Research Facility
mi
from
Atlanta, GA
First Time Use of SD-809 in Huntington Disease
A Randomized Double Blind, Placebo Controlled Study of SD-809 Extended Release for the Treatment of Chorea Associated With Huntington Disease
Status: Enrolling
Updated: 7/31/2014
Clinical Research Facility
mi
from
Atlanta, GA
Click here to add this to my saved trials
First Time Use of SD-809 in Huntington Disease
A Randomized Double Blind, Placebo Controlled Study of SD-809 Extended Release for the Treatment of Chorea Associated With Huntington Disease
Status: Enrolling
Updated:  7/31/2014
Clinical Research Facility
mi
from
Indianapolis, IN
First Time Use of SD-809 in Huntington Disease
A Randomized Double Blind, Placebo Controlled Study of SD-809 Extended Release for the Treatment of Chorea Associated With Huntington Disease
Status: Enrolling
Updated: 7/31/2014
Clinical Research Facility
mi
from
Indianapolis, IN
Click here to add this to my saved trials
First Time Use of SD-809 in Huntington Disease
A Randomized Double Blind, Placebo Controlled Study of SD-809 Extended Release for the Treatment of Chorea Associated With Huntington Disease
Status: Enrolling
Updated:  7/31/2014
Clinical Research Facility
mi
from
Iowa City, IA
First Time Use of SD-809 in Huntington Disease
A Randomized Double Blind, Placebo Controlled Study of SD-809 Extended Release for the Treatment of Chorea Associated With Huntington Disease
Status: Enrolling
Updated: 7/31/2014
Clinical Research Facility
mi
from
Iowa City, IA
Click here to add this to my saved trials
First Time Use of SD-809 in Huntington Disease
A Randomized Double Blind, Placebo Controlled Study of SD-809 Extended Release for the Treatment of Chorea Associated With Huntington Disease
Status: Enrolling
Updated:  7/31/2014
Clinical Research Facility
mi
from
Kansas City, KA
First Time Use of SD-809 in Huntington Disease
A Randomized Double Blind, Placebo Controlled Study of SD-809 Extended Release for the Treatment of Chorea Associated With Huntington Disease
Status: Enrolling
Updated: 7/31/2014
Clinical Research Facility
mi
from
Kansas City, KA
Click here to add this to my saved trials
First Time Use of SD-809 in Huntington Disease
A Randomized Double Blind, Placebo Controlled Study of SD-809 Extended Release for the Treatment of Chorea Associated With Huntington Disease
Status: Enrolling
Updated:  7/31/2014
Clinical Research Facility
mi
from
Wichita, KA
First Time Use of SD-809 in Huntington Disease
A Randomized Double Blind, Placebo Controlled Study of SD-809 Extended Release for the Treatment of Chorea Associated With Huntington Disease
Status: Enrolling
Updated: 7/31/2014
Clinical Research Facility
mi
from
Wichita, KA
Click here to add this to my saved trials
First Time Use of SD-809 in Huntington Disease
A Randomized Double Blind, Placebo Controlled Study of SD-809 Extended Release for the Treatment of Chorea Associated With Huntington Disease
Status: Enrolling
Updated:  7/31/2014
Clinical Research Facility
mi
from
Louisville, KY
First Time Use of SD-809 in Huntington Disease
A Randomized Double Blind, Placebo Controlled Study of SD-809 Extended Release for the Treatment of Chorea Associated With Huntington Disease
Status: Enrolling
Updated: 7/31/2014
Clinical Research Facility
mi
from
Louisville, KY
Click here to add this to my saved trials